Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of cisplatin + paclitaxel versus topotecan + paclitaxel, with or without bevacizumab, in persistent, recurrent, or stage IVB cervical cancer
2010-023525-38Phase 3Active
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Dec 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab, cisplatin, paclitaxel and topotecan in Cervical Cancer (CC) (4 arms), sponsored by Grupo Español de Investigación en Cáncer de Ovario. Primary endpoint: overall survival. Started Dec 2010; status: active.
02
Drugs
bevacizumabcisplatinpaclitaxeltopotecan
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2010-023525-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023525-38.